Search Clinical Trials
Sponsor Condition of Interest |
---|
Viral Specific T Cell Therapy for COVID-19 Related Pneumonia
M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed
This early phase I trial identifies the feasibility, possible benefits and/or side
effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating
cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection, the virus responsible for coronavirus... expand
This early phase I trial identifies the feasibility, possible benefits and/or side effects of administering SARS-CoV-2 specific cytotoxic T lymphocytes (CTLs) in treating cancer patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the virus responsible for coronavirus disease 2019 (COVID-19). SARS-CoV-2 Specific CTLs are a type of immune cells that are made from donated blood cells grown in the laboratory and are designed to kill cells infected with SARS-CoV-2 virus. Giving CTLs may help control the COVID-19 in cancer patients. Type: Interventional Start Date: Dec 2020 |
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform...
ImmunityBio, Inc.
Covid19
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is
designed to assess the safety, reactogenicity, and immunogenicity the combination of
hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule)
and to select an optimal combination dose... expand
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and hAd5-S-Fusion+N-ETSD (Oral capsule) and to select an optimal combination dose for future studies. Type: Interventional Start Date: Feb 2021 |
NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients
Notitia Biotechnologies Company
Suspected or Confirmed COVID-19
This open-label, randomized, and controlled clinical trial aims to determine the
feasibility and effectiveness of using NBT-NM108, a novel botanical-based
fixed-combination drug, to modulate the gut microbiota and treat early-stage suspected or
confirmed symptomatic COVID-19 patients. expand
This open-label, randomized, and controlled clinical trial aims to determine the feasibility and effectiveness of using NBT-NM108, a novel botanical-based fixed-combination drug, to modulate the gut microbiota and treat early-stage suspected or confirmed symptomatic COVID-19 patients. Type: Interventional Start Date: Nov 2021 |
The Measurement of Chemicals in Exhaled Breath Can Identify if a Person is Infected With COVID-19
N5 Sensors
COVID-19
The type and number of chemicals in exhaled breath are different in people with infection
as compared to those without infection. In this study, the breath of people with and
without COVID infection will be measured. Changes in the amount and type of chemicals in
breath will be used to determine if... expand
The type and number of chemicals in exhaled breath are different in people with infection as compared to those without infection. In this study, the breath of people with and without COVID infection will be measured. Changes in the amount and type of chemicals in breath will be used to determine if an individual does or does not have COVID infection. If the measurements of breath are a reliable measure of COVID infection, this device may be used to rapidly screen people who are attending large public events (for example, music concert or baseball game) to minimize the spread of COVID at the event. Type: Observational Start Date: Aug 2024 |
Assessment of Fit of Novel N95 Style Transparent Face Masks
Brigham and Women's Hospital
Respiratory Disease
Infection, Coronavirus
Respiratory Tract Infections
Face masks have become a critically important public health intervention after the
COVID-19 pandemic. Multiple types of masks ranging from full face filtering to cloth
masks have been developed and commercialized to facilitate protection against respiratory
pathogens. Most of these systems are made... expand
Face masks have become a critically important public health intervention after the COVID-19 pandemic. Multiple types of masks ranging from full face filtering to cloth masks have been developed and commercialized to facilitate protection against respiratory pathogens. Most of these systems are made with opaque fabrics and may prevent individuals from expressing emotions or for those who are deaf and hard of hearing, communicating. To date, few transparent face masks which also confer respiratory pathogen protection have been developed. This study will test the feasability and acceptability of two new masks, the SEEUS-95 mask and CrystalGuard mask which are both transparent versions of N-95 filtering face masks. Type: Interventional Start Date: Oct 2024 |
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic...
Aligos Therapeutics
COVID-19
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of
ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic
impairment, matched for age, body weight and, to the extent possible, for gender. The
primary purpose of this study is to characterize... expand
This is a Phase 1 non-randomized, open-label, multiple dose, parallel-group study of ALG-097558 in subjects with moderate hepatic impairment and subjects without hepatic impairment, matched for age, body weight and, to the extent possible, for gender. The primary purpose of this study is to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses. Type: Interventional Start Date: Sep 2024 |
Diet and Fasting for Long COVID
Pacific Northwest University of Health Sciences
Long Covid19
Long COVID
This cross-over study will assess a no added sugar diet, a restricted daily eating
window, and one or two full day water fasts to determine if there is an effect on
self-reported symptoms of Long Covid (PASC). expand
This cross-over study will assess a no added sugar diet, a restricted daily eating window, and one or two full day water fasts to determine if there is an effect on self-reported symptoms of Long Covid (PASC). Type: Interventional Start Date: Nov 2022 |
PROTECT-APT 1: Early Treatment and Post-Exposure Prophylaxis of COVID-19
Henry M. Jackson Foundation for the Advancement of Military Medicine
SARS-CoV-2
This study is an adaptive, randomized, double blind, platform trial evaluating promising
investigational products (IP) for safety and efficacy as early outpatient treatment and
post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2
(SARS-CoV-2). expand
This study is an adaptive, randomized, double blind, platform trial evaluating promising investigational products (IP) for safety and efficacy as early outpatient treatment and post-exposure prophylaxis for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Type: Interventional Start Date: Jan 2024 |
Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study
AstraZeneca
COVID-19
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of
AZD3152 in healthy adult male and female participants, across different dose levels and
routes of administration (ie, Intramuscular [IM] injection and Intravenous [IV]
infusion). expand
This is a dose exploration study to evaluate the safety and pharmacokinetics (PK) of AZD3152 in healthy adult male and female participants, across different dose levels and routes of administration (ie, Intramuscular [IM] injection and Intravenous [IV] infusion). Type: Interventional Start Date: May 2023 |
Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement
Yale University
COVID-19
The goal of this study is to reduce morbidity and mortality from COVID-19 amongst people
who are detained in and work in correctional facilities. The overall objective is to
identify feasible and effective interventions to improve vaccine uptake in correctional
facilities and study the effectiveness... expand
The goal of this study is to reduce morbidity and mortality from COVID-19 amongst people who are detained in and work in correctional facilities. The overall objective is to identify feasible and effective interventions to improve vaccine uptake in correctional facilities and study the effectiveness of these interventions through rapid cycle, cluster randomized trials in the Pennsylvania prison system. Type: Interventional Start Date: Jul 2024 |
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
CyanVac LLC
COVID-19
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered
as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will
enroll up to 400 healthy participants, age 18-80 years. expand
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants. The trial will enroll up to 400 healthy participants, age 18-80 years. Type: Interventional Start Date: Jun 2023 |
A Pilot Randomized Controlled Trial: CoINTEGRATE
University of Michigan
Neurocognitive Disorders
Cognitive Dysfunction
Traumatic Brain Injury
Multiple Sclerosis
Mild Cognitive Impairment
The purpose of this study is to examine the feasibility of comprehensive multimodal
individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation
Therapy (CRT), and modifiable lifestyle sessions.
The study team hypothesizes that combining evidence-based cognitive and affective
therapies... expand
The purpose of this study is to examine the feasibility of comprehensive multimodal individually tailored Cognitive Behavioral Therapy (CBT), Cognitive Rehabilitation Therapy (CRT), and modifiable lifestyle sessions. The study team hypothesizes that combining evidence-based cognitive and affective therapies with lifestyle modifications is feasible and will improve the community integration (CI) and Quality of life (QoL) in patients with a neurocognitive disorder compared to usual care. Type: Interventional Start Date: Sep 2023 |
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients With Post-COVID Syndrome
StemCyte, Inc.
Long COVID
Post-COVID Syndrome
Post COVID-19 Condition
RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID. expand
RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID. Type: Interventional Start Date: May 2023 |
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Atea Pharmaceuticals, Inc.
SARS CoV 2 Infection
COVID-19
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe
in adults with COVID-19 who do not need to be in the hospital but who are at high risk
for progression to severe disease. Eligible subjects will be randomly assigned (by
chance) to receive BEM or matching placebo... expand
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days. Type: Interventional Start Date: Nov 2022 |
Phase 2a MIB-626 vs. Placebo COVID-19
Metro International Biotech, LLC
Covid19
Stage 1 Acute Kidney Injury
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with
COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in
preventing worsening of kidney function, as assessed by longitudinal changes in serum
creatinine concentration, and in attenuating... expand
The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19 infection and stage 1 acute kidney injury is more efficacious than placebo in preventing worsening of kidney function, as assessed by longitudinal changes in serum creatinine concentration, and in attenuating the inflammatory response to the infection. Type: Interventional Start Date: Oct 2021 |
Post COVID-19 Biorepository
University of Kansas Medical Center
Coronavirus Infection
Establish a biorepository, clinical data registry, and radiographic image database from
individuals who were COVID positive at one time and are being seen for outpatient
follow-up or a separate study visit. expand
Establish a biorepository, clinical data registry, and radiographic image database from individuals who were COVID positive at one time and are being seen for outpatient follow-up or a separate study visit. Type: Observational [Patient Registry] Start Date: Feb 2021 |
SARS-COV2 Pandemic Serosurvey in a Rare Disease Population
National Institute of Allergy and Infectious Diseases (NIAID)
SARS-COV2 Virus
Background:
The SARS-COV2 outbreak has had a major impact on the economy and society. Researchers
want to learn how widespread the infection is in the rare disease community. To do this,
they will get blood samples from people with rare diseases. They will use at-home
sampling. This will allow... expand
Background: The SARS-COV2 outbreak has had a major impact on the economy and society. Researchers want to learn how widespread the infection is in the rare disease community. To do this, they will get blood samples from people with rare diseases. They will use at-home sampling. This will allow them to get samples from people across a wide area. Objective: To estimate the proportion of people with rare diseases who have SARS-COV2 antibodies in the National Center for the Advancement of Translational Sciences Rare Disease Clinical Research Network (RDCRN) Rare Diseases Survey over time. Eligibility: People under age 90 who have a rare disease and have taken part in the Cincinnati Children s Hospital Medical Center (CCHMC) protocol# 2020-0299. Design: RDCRN will tell CCHMC participants about this NIH study. RDCRN will only reach out to those who agreed to be contacted for future studies. They will be contacted by phone and email. Participants will have a virtual visit to collect data. It will take place over the phone. Participants will be sent a home kit to collect a blood sample. The kit contains gauze, a lancet, bandages, a collection device, and instructions. They will also be given shipping materials. They will give up to 80ul of blood. They will ship the sample back to NIH. Participants will complete a survey. It can be done online or over the phone. Participation will last for 1 week.... Type: Observational Start Date: Apr 2021 |
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
M.D. Anderson Cancer Center
COVID-19 Infection
COVID-19-Associated Acute Respiratory Distress Syndrome
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Symptomatic COVID-19 Infection Laboratory-Confirmed
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I
study is the feasibility of treating patients with acute respiratory distress syndrome
(ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem
cells (MSC). The purpose of the phase... expand
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with cord blood-derived mesenchymal stem cells (MSC). The purpose of the phase II trial is to compare the effect of MSC with standard of care in these patients. MSCs are a type of stem cells that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of COVID-19 related ARDS. Type: Interventional Start Date: Jul 2020 |
Home-based Kidney Care in Native Americans of New Mexico (HBKC) - Enhancement: COVID-19 Study
University of New Mexico
CKD
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) OR COVID-19 related
Addition: The aim of this addition activity is to track the impact of the COVID-19
epidemic on participants with diabetes and chronic kidney disease (CKD). Investigators
have modified the original HBKC Study protocol... expand
Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) OR COVID-19 related Addition: The aim of this addition activity is to track the impact of the COVID-19 epidemic on participants with diabetes and chronic kidney disease (CKD). Investigators have modified the original HBKC Study protocol to expand data currently collected from study participants to include data in the following domains linked to the COVID-19 epidemic: symptoms of COVID-19 disease, access to healthcare, and impact on health related behaviors (such as medication adherence, physical activity, dietary behaviors, smoking, and alcohol use). Type: Observational Start Date: Jan 2021 |
ACTIV-2: A Study for Outpatients With COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus
Covid19
Drug studies often look at the effect one or two drugs have on a medical condition, and
involve one company. There is currently an urgent need for one study to efficiently test
multiple drugs from more than one company, in people who have tested positive for
COVID-19 but who do not currently need... expand
Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications, and spread of COVID-19 in the community. This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. In Phase II, participants in the study will be treated with either a study drug or with placebo. In protocol version 7.0, participants in Phase III of the study will be treated with either a study drug or active comparator drug. Participants assigned to the bamlanivimab agent/placebo arm and will have 28 days of intensive follow-up following study drug administration, followed by limited follow-up through 24 weeks in phase II and in phase III. All other investigational agents and their corresponding placebo arms will involve 28 days of intensive follow-up, followed by limited follow-up through 72 weeks in phase II and phase III. Additional study visits may be required, depending on the agent. Type: Interventional Start Date: Aug 2020 |
Impact of the COVID-19 Pandemic and HRQOL in Cancer Patients and Survivors
M.D. Anderson Cancer Center
COVID-19 Infection
Malignant Solid Neoplasm
This study uses questionnaires to gain an understanding of how experiences during the
COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related
quality of life (HRQOL) and other areas such as COVID-19-specific psychological distress,
disruptions to health care, finances and... expand
This study uses questionnaires to gain an understanding of how experiences during the COVID-19 pandemic, regardless of COVID-19 status, may have impacted health-related quality of life (HRQOL) and other areas such as COVID-19-specific psychological distress, disruptions to health care, finances and social interactions in cancer patients. The coronavirus disease 2019 (COVID-19) is an infectious disease that is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The information learned from this study will guide the development of psychosocial programs to improve patient care and outcomes in cancer patients and survivors in the context of facing a global pandemic. Type: Observational Start Date: May 2020 |
Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19...
MediciNova
Pneumonia, Viral
The study aims to evaluate MN-166 (ibudilast) in patients with COVID-19 who are at risk
of developing acute respiratory distress syndrome. Subjects will be screened, randomly
assigned to MN-166 or placebo groups, receive study drug on Days 1-7, and followed up on
Day 14 and Day 28. expand
The study aims to evaluate MN-166 (ibudilast) in patients with COVID-19 who are at risk of developing acute respiratory distress syndrome. Subjects will be screened, randomly assigned to MN-166 or placebo groups, receive study drug on Days 1-7, and followed up on Day 14 and Day 28. Type: Interventional Start Date: Jan 2021 |
Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)
Columbia University
COVID-19
Corona Virus Infection
The purpose of this study is to test the hypothesis that post-exposure prophylaxis with
hydroxychloroquine will reduce the symptomatic secondary attack rate among household
contacts of known or suspected COVID-19 patients. expand
The purpose of this study is to test the hypothesis that post-exposure prophylaxis with hydroxychloroquine will reduce the symptomatic secondary attack rate among household contacts of known or suspected COVID-19 patients. Type: Interventional Start Date: Mar 2020 |
Women s Health Awareness Community Resiliency, Environmental Action and Collaborations for Health (REACH)...
National Institute of Environmental Health Sciences (NIEHS)
Mental Health
Background:
Inequalities in COVID-19 infection, hospitalization, and death in under-studied,
under-represented, and under-reported groups of people are severe. A growing number of
studies have assessed the impact of individual risk factors. But few studies have
assessed which factors are the greatest... expand
Background: Inequalities in COVID-19 infection, hospitalization, and death in under-studied, under-represented, and under-reported groups of people are severe. A growing number of studies have assessed the impact of individual risk factors. But few studies have assessed which factors are the greatest drivers of COVID-19 disparities from a wider perspective. Objective: To understand the long-term impacts of COVID-19 on minority women and their families to assist in developing community-based programs to help in recovery. Eligibility: Healthy people aged 18 and older who reside in North Carolina. Design: Participants will take a 45-minute online survey. The survey will cover their demographics, community, health, lifestyle, household, and environment. Participants may choose to have tests. They may visit the Clinical Research Unit. They may also have a home visit for these tests. In some cases, they may mail samples to the study team in prepaid envelopes. Participants may take an optional 15 minute survey about their reproductive history. Participants may give a blood sample. Participants may give a urine sample. They will fill out a log and return with their sample. Participants may give saliva samples. Participants may give toenail samples from each toe. Participants may give dust samples. They will be given 8 alcohol swabs. Two will be for testing. They will be asked to swipe a total of 3 door frames. Each door frame should be in a different room of the house. Participants may be given silicone wristbands to wear for 1 week. This is to measure their exposure to air pollutants. Participants may be contacted in the future for follow-up. They may be contacted by phone, email, or letter. Type: Observational Start Date: Jun 2023 |
COVID-19 Experiences in the SELF Cohort
National Institute of Environmental Health Sciences (NIEHS)
COVID-19
Background:
COVID-19 affected African Americans more than Whites. African Americans, especially
women, have had higher rates of COVID-19 infections compared to Whites. They are also
more likely to go to the hospital or die of this disease. Many researchers who looked
into these issues lacked background... expand
Background: COVID-19 affected African Americans more than Whites. African Americans, especially women, have had higher rates of COVID-19 infections compared to Whites. They are also more likely to go to the hospital or die of this disease. Many researchers who looked into these issues lacked background data on the people they studied. SELF is a 10-year study of fibroids in African American women aged 23-35. Researchers already have a lot of data on these women. Asking how COVID-19 affected them can add context other studies lack. Objective: To describe the impact of the COVID-19 pandemic on young African American women and their families. Eligibility: Participants must be enrolled in SELF (Study of Environment, Lifestyle, and Fibroids). Design: Researchers will invite all women enrolled in SELF to participate in this natural history study. Participants will complete one questionnaire. They will answer the questions online. They may also choose to get a paper copy sent by mail. The survey will take no more than 15-20 minutes. All questions will relate to COVID-19. Participants will be asked if they had COVID-19. They will be asked if family, friends, or members of their community did. They will answer questions about their vaccine status and access to health care services. Participants will also answer questions about how the pandemic affected their lives. They will be asked about their job and if finding childcare was a challenge. They will be asked about money problems and how they coped. They will be asked about sleep problems and emotional distress. Participants will get a $30 gift card after they finish the survey. Type: Observational Start Date: Jun 2022 |
- Previous
- Next